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To examine the contribution of different G-protein
pathways to lysophosphatidic acid (LPA)-induced pro-
tein kinase D (PKD) activation, we tested the effect of
LPA on PKD activity in murine embryonic cell lines
deficient in Gq/11 (Gq/11 KO cells) or G12/13 (G12/13 KO
cells) and used cells lacking rhodopsin kinase (RK cells)
as a control. In RK and G12/13 KO cells, LPA induced
PKD activation through a phospholipase C/protein ki-
nase C pathway in a concentration-dependent fashion
with maximal stimulation (6-fold for RK cells and 4-fold
for G12/13 KO cells in autophosphorylation activity)
achieved at 3 M. In contrast, LPA did not induce any
significant increase in PKD activity in Gq/11 KO cells.
However, LPA induced a significantly increased PKD
activity when Gq/11 KO cells were transfected with Gq.
LPA-induced PKD activation was modestly attenuated
by prior exposure of RK cells to pertussis toxin (PTx)
but abolished by the combination treatments of PTx and
Clostridium difficile toxin B. Surprisingly, PTx alone
strikingly inhibited LPA-induced PKD activation in a
concentration-dependent fashion in G12/13 KO cells.
Similar results were obtained when activation loop
phosphorylation at Ser-744 was determined using an
antibody that detects the phosphorylated state of this
residue. Our results indicate that Gq is necessary but
not sufficient to mediate LPA-induced PKD activation.
In addition to Gq, LPA requires additional G-protein
pathways to elicit a maximal response with Gi playing a
critical role in G12/13 KO cells. We conclude that LPA
induces PKD activation through Gq, Gi, and G12 and
propose that PKD activation is a point of convergence in
the action of multiple G-protein pathways.
Protein kinase C (PKC),1 a major target for the tumor pro-
moting phorbol esters, has been implicated in the signal trans-
duction pathways regulating a wide range of biological re-
sponses, including changes in cell morphology, differentiation,
and proliferation (1, 2). Molecular cloning has demonstrated
the presence of multiple PKC isoforms (2–5), i.e. conventional
PKCs (, 1, 2, and ), novel PKCs (, , , and ), and atypical
PKCs ( and 	) all of which possess a highly conserved catalytic
domain.
PKD/PKC
 is a serine/threonine protein kinase (6, 7) with
distinct structural, enzymological, and regulatory properties
(8). In particular, PKD is rapidly activated in intact cells
through a mechanism that involves phosphorylation (8). Spe-
cifically, exposure of intact cells to phorbol esters, cell-per-
meant diacylglycerols, or bryostatin induces rapid PKD phos-
phorylation and activation, which is maintained during cell
lysis and immunoprecipitation (8–13). Several lines of evi-
dence, including the use of PKC-specific inhibitors and co-
transfection of PKD with constitutively active PKC mutants
indicate that PKD is activated through a novel PKC-dependent
signal transduction pathway in vivo (9–11). The residues Ser-
744 and Ser-748 in the activation loop of PKD have been
identified as critical phosphorylation sites in PKD activation
(14, 15). Taken together, these results suggest an important
connection between PKCs and PKD and indicate that PKD can
function downstream of PKC in a novel signal transduction
pathway.
Heterotrimeric guanine nucleotide-binding regulatory pro-
teins (G proteins) are composed of , , and  subunits and
transduce external signals from heptahelical receptors to in-
tracellular effectors (16). Mammalian G protein  subunits are
classified into four subfamilies: Gs, Gi, Gq, and G12. The 
subunit of Gq stimulates the  isoforms of phospholipase C
(PLC), which catalyze the production of inositol 1,4,5-trisphos-
phate that triggers the release of Ca2 from internal stores and
diacylglycerol that activates the classical and novel isoforms of
PKC (reviewed in Ref. 17). A variety of neuropeptide agonists
that signal through heptahelical receptors and couple to het-
erotrimeric G proteins, including bombesin, bradykinin, endo-
thelin, and vasopressin, induce rapid PKD activation in normal
and neoplastic cells (11, 13, 18, 19). Although each of these
receptors activates Gq and Gq signaling stimulates PKD ac-
tivity (20), expression of a COOH-terminal fragment of Gq
that acts in a dominant-negative fashion, attenuated (but did
not eliminate) PKD activation in response to agonist stimula-
tion of bombesin receptor (20). These results suggested that G
protein-coupled receptors (GPCRs) stimulate PKD activation
not only via Gq but also through other G protein-mediated
signaling pathways.
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Many GPCRs also interact with other heterotrimeric G pro-
teins including members of the G12 family, which mediate
activation of the low molecular weight G proteins of the Rho
subfamily (21–26) via guanine nucleotide exchange factors that
directly link the G subunits to Rho (27–29). Rho plays a major
role in promoting cytoskeletal responses including formation of
actin stress fibers, assembly of focal adhesions, and tyrosine
phosphorylation of focal adhesion proteins and has been impli-
cated in gene expression, cell migration, proliferation, and
transformation (30–32). Interestingly, a number of recent stud-
ies have suggested a convergence between Rho- and PKC-
mediated signaling in yeast and mammalian cells (33–38). For
example, Slater et al. (37) have demonstrated that Rho-GTP
potently stimulates PKC activity in vitro using recombinant
proteins and Sagi et al. (38) reported that Gq and PLC signal-
ing are synergistic with Rho. Recently, we demonstrated that
in addition to Gq, Rho- and G13-mediated signaling can pro-
mote PKD activation in intact cells and that endogenous Rho
and G13 contribute to PKD activation in response to bombesin
GPCR stimulation (39). Thus, our results identified PKD as a
novel downstream target in G13 and Rho signaling and indi-
cated that GPCR stimulation promotes PKD activation via
both Gq- and G13/Rho-dependent pathways.
Lysophosphatidic acid (LPA), a major bioactive lipid of se-
rum (40), elicits a plethora of biological responses by activation
of its specific GPCRs (41–43). Thus far, three genes (lpA1, lpA2,
and lpA3) encoding LPA receptors, LPA1/EDG-2, LPA2/EDG-4,
and LPA3/EDG-7, have been identified in mammals (43–45).
All LPA receptors are coupled to Gi and Gq and, at least LPA1
and LPA2 are also coupled to G12 (42, 45, 46). LPA induces Ras
activation leading to stimulation of Raf, MEK, and the ERKs
via a pertussis toxin (PTx)-sensitive pathway that involves the
 subunits of Gi (47–51) while the  subunit of this trimeric G
protein mediates inhibition of adenylate cyclase activity (42,
46). LPA stimulates PLC-mediated generation of inositol 1,4,5-
trisphosphate and diacylglycerol, leading to Ca2 mobilization
from intracellular stores and PKC activation, respectively.
These PLC-dependent responses are mediated by the  subunit
of Gq and/or the  subunits of the PTx-sensitive Gi (52). LPA
also promotes PTx-insensitive stress fiber formation, assembly
of focal adhesions, and tyrosine phosphorylation of focal adhe-
sion proteins (53) via activation of G13 and Rho (24, 54).
Because LPA receptors are expressed in most cell types, this
bioactive lipid is a prototype agonist that promotes the activa-
tion of multiple endogenous G protein pathways that are re-
sponsible for transducing LPA signals into a broad spectrum of
biological responses (43, 45, 55).
LPA has also been shown to induce a rapid PKC-dependent
PKD activation in intact Swiss 3T3, Rat-1, and IEC-6 cells (56,
57). Interestingly, treatment of these cells with PTx markedly
attenuated PKD activation in response to LPA. These results
identified the involvement of an additional Gi-dependent path-
way leading to PKD activation and indicated that the endoge-
nous Gq pathway is not sufficient to promote PKD activation in
response to LPA. Because our previous studies demonstrated
that PKD can be activated through Gq- and G12-dependent
pathways (see above) and because LPA receptors are also cou-
pled to Gq and G12, we hypothesized that LPA induces PKD
through multiple G protein signal transduction pathways.
Here, we tested this hypothesis using mouse embryonic cell
lines deficient in Gq/11 (Gq/11 KO cells) or G12/13 (G12/13 KO
cells), and used a cell line lacking rhodopsin kinase (RK cells),
as a control. Based on our results, we conclude that LPA in-
duces PKD activation through the cooperation of Gq with either
Gi or G12 and that PKD activation is a point of convergence in
the action of multiple G protein pathways.
EXPERIMENTAL PROCEDURES
Cell Culture—Mouse embryonic fibroblasts were generated from ge-
netically engineered mice (58, 59) that contained gene knockout for
rhodopsin kinase, Gq/11, and G12/13. Stock cultures of these cells were
maintained in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum and 250 
g/ml G418 in a humidified atmo-
sphere containing 10% CO2 and 90% air at 37 °C. For experimental
purposes, cells were plated in 60- or 100-mm dishes at about 30%
confluency in Dulbecco’s modified Eagle’s medium containing 10% fetal
bovine serum and 250 
g/ml G418 and were allowed to grow to near
confluency (6–7 days) and then changed to serum-free Dulbecco’s mod-
ified Eagle’s medium for 8–24 h prior to the experiment.
Cell Transfection and cDNA Constructs Used in Transfections—To
transfect the cells, RK cells and Gq/11 KO cells were subcultured to
80–90% confluency in 10-cm dishes. All transfections and cotransfec-
tions were carried out with equivalent amounts of DNA (20 
g/dish).
Transfections were carried out in Opti-MEM using LipofectAMINE
2000 reagent according to the protocol from the manufacturer (Invitro-
gen). Cells were used for experiments 48–72 h after of transfection.
Chimeric fusion proteins between GFP and PKD (GFP-PKD) have been
described previously (69, 70).
Immunoprecipitation—Cultures of RK, Gq/11, and G12/13 cells,
treated as described in the individual experiments, were washed and
lysed in lysis buffer (50 mM Tris/HCl, pH 7.6, 2 mM EGTA, 2 mM EDTA,
1 mM dithiothreitol, 10 
g/ml aprotinin, 10 
g/ml leupeptin, 1 mM
4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride, and 1% Tri-
ton X-100). Cell lysates were clarified by centrifugation at 15,000  g
for 10 min at 4 °C. PKD was immunoprecipitated at 4 °C for 2–4 h with
the PA-1 antiserum (1:100) or with GFP antibody for GFP-PKD trans-
fected cell lysates, as previously described (9, 10). The immune com-
plexes were recovered using protein A coupled to agarose.
Kinase Assay of PKD—PKD autophosphorylation was determined in
an in vitro kinase assay by mixing 20 
l of PKD immunocomplexes with
10 
l of a phosphorylation mixture containing (final concentration) 100

M [-32P]ATP (specific activity 400–600 cpm/pmol), 30 mM Tris/HCl,
pH 7.4, 10 mM MgCl2, and 1 mM dithiothreitol. After 10 min of incuba-
tion at 30 °C, the reaction was stopped by washing with 1 ml of kinase
buffer and then adding an equal volume of 2 SDS-PAGE sample
buffer (200 mM Tris/HCl, pH 6.8, 2 mM EDTA, 0.1 M Na3VO4, 6% SDS,
10% glycerol, and 4% 2-mercaptoethanol), followed by SDS-PAGE anal-
ysis (9, 60). The gels were dried and the 110- or 140-kDa radioactive
band corresponding to autophosphorylated PKD or GFP-PKD was vi-
sualized by autoradiography. Autoradiographs were scanned in a GS-
710 Calibrated Imaging Densitometer (Bio-Rad), and the labeled band
was quantified using the Quantity OneTM software program.
Exogenous substrate phosphorylation by immunoprecipitated PKD
was carried out by mixing 20 
l of the washed immunocomplexes with
20 
l of a phosphorylation mixture containing 2.5 mg/ml syntide-2
(PLARTLSVAGLPGKK), a peptide based on phosphorylation site two of
glycogen synthase. After 10 min of incubation at 30 °C, the reaction was
stopped by adding 100 
l of 75 mM H3PO4, and 75 
l of the supernatant
was spotted on P-81 phosphocellulose paper. Free [-32P]ATP was sep-
arated from the labeled substrate by washing the P-81 paper four times
for 5 min, in 75 mM H3PO4. The papers were dried, and the radioactivity
incorporated into syntide-2 was determined by Cerenkov counting.
Western Blot Analysis for pS744/748 and ERK-2/ERK-1 Activa-
tion—Samples of cell lysates were directly solubilized by boiling in 2
SDS-PAGE sample buffer. Following SDS-PAGE on 8% gels, proteins
were transferred to Immobilon-P membranes (Millipore) and blocked by
3–6 h incubation with 5% nonfat milk in phosphate-buffered saline, pH
7.2. Membranes were then incubated 3 h with the respective antibodies.
PKD phosphorylation was determined by incubating the membrane
with an antibody that specifically recognizes the phosphorylated state
of serine 744 and serine 748 of PKD at a dilution of 1:1000 in phosphate-
buffered saline, 0.1% Tween 20 containing 5% bovine serum albumin.
Activation of ERK-2 and ERK-1 occurs through phosphorylation of
specific threonine and tyrosine residues, resulting in slower migrating
forms in SDS-PAGE gels. These activated forms were monitored by
using a specific antiphospho-ERK-1/ERK-2 monoclonal antibody that
recognizes the phosphorylated state of Thr-202 and Tyr-204 of ERL-1/2
at a dilution of 1:1000 in phosphate-buffered saline, 0.1% Tween 20
containing 5% nonfat dried milk. The same membranes were stripped
and probed in a similar fashion with goat anti-ERK-2 polyclonal
antibody.
Horseradish peroxidase-conjugated anti-rabbit IgG antibody (1:5000,
Amersham Biosciences) was then applied for 1 h at room temperature
after washing 3 times with phosphate-buffered saline containing 0.05%
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Tween. Immunoreactive bands were detected by enhanced chemilumi-
nescence Western blotting ECLTM reagents.
Materials—[-32P]ATP (370 MBq/ml), horseradish peroxidase-conju-
gated donkey anti-rabbit IgG, and enhanced chemiluminescence re-
agents were from Amersham Biosciences. Protein-A agarose and 4-(2-
aminoethyl)-benzenesulfonyl fluoride hydrochloride were from Roche
Molecular Biochemicals. LPA, PDB, GF 109203X, GF V, U-0126, PD
098059, and Clostridium difficile toxin B were obtained from Sigma. Ro
31-8220, U73122, and PTx were purchased from Calbiochem (La Jolla,
CA). Opti-MEM and LipofectAMINE 2000 reagent were from Invitro-
gen. PA-1 antiserum was raised against the synthetic peptide EE-
REMKALSERVSIL that corresponds to the carboxyl-terminal region of
the predicted amino acid sequence of PKD, as previously described (9,
60). Phospho-PKD Ser-744/748 antibody was obtained from Cell Sig-
naling Technology (Beverly, MA). Anti-phospho-ERK-1/2 monoclonal
antibody was obtained from New England Biolabs. Anti-Gq/11, anti-
G12/13, anti-GFP, and anti-ERK-2 polyclonal antibodies were from
Santa Cruz Biotechnologies (Palo Alto, CA). Other items were from
standard suppliers or as specifically indicated.
RESULTS AND DISCUSSION
LPA Induces PKD Activation in RK Cells through a PKC-de-
pendent Pathway—To examine the contribution of different G
protein pathways to LPA-induced PKD activation, we decided
to test the effect of this agonist on PKD activity isolated from
murine embryonic cell lines lacking RK, Gq/11, and G12/13.
Initially, we determined whether LPA induces PKD activation
in RK cells, used as controls. Cultures of these cells were
stimulated with increasing concentrations of LPA (0.01–10 
M)
for 10 min and lysed. PKD was immunoprecipitated from the
extracts of these cells and the immune complexes were incu-
bated with [-32P]ATP, subjected to SDS-PAGE, and analyzed
by autoradiography to detect the prominent 110-kDa band
corresponding to autophosphorylated PKD.
The results presented in Fig. 1A show that LPA induced a
marked increase in PKD autophosphorylation activity in a
concentration-dependent fashion in RK cells. Half-maximal
and maximal stimulation (6-fold increase) were achieved at
0.07 and 3 
M, respectively. As illustrated in the inset to Fig. 1,
similar results were obtained when PKD activity in immuno-
complexes was determined by phosphorylation of syntide-2 (61,
62), a synthetic peptide previously demonstrated to be an ex-
cellent substrate for PKD (6).
We previously proposed that phosphorylation of Ser-744 and
Ser-748 within the PKD activation loop plays a critical role in
PKD activation (14, 15, 20). Recently, a novel antibody recog-
nizing predominantly the phosphorylated state of Ser-744
(pS744/pS748) in PKD was used in our laboratory to monitor
activation loop phosphorylation in response to phorbol ester
and bombesin (15). To examine whether LPA induces activa-
tion loop phosphorylation in the RK cells, lysates from these
cells treated with increasing concentrations of LPA were ana-
lyzed by SDS-PAGE, followed by Western blotting with the
pS744/748 antibody. As shown in Fig. 1A, LPA induced PKD
Ser-744 phosphorylation in a concentration-dependent fashion
in RK cells with maximal stimulation achieved at 3 
M.
To determine whether LPA induces PKD activation and ac-
tivation loop phosphorylation through a PKC-mediated path-
way in RK cells, we used inhibitors that discriminate between
PKCs and PKD. RK cells were treated for 1 h with the inhibi-
tors of phorbol ester-sensitive isoforms of PKC, GF I (also
known as GF 109203X or bisindolylmaleimide I) or Ro 31-8220
(64, 65), prior to stimulation with 3 
M LPA. As shown in Fig.
1B (left panels), exposure to either GF I or Ro 31-8220 pre-
vented PKD activation (top) and Ser-744 phosphorylation (mid-
dle) induced by LPA. In contrast, the compound GFV, which is
structurally related to GF I but biologically inactive, did not
prevent PKD activation and phosphorylation in response to
LPA in RK cells. Similar results were obtained when PKD
activity in immunocomplexes was determined by assays of
FIG. 1. LPA activates PKD in a dose-dependent and PLC/PKC-
dependent manner in RK cells. A, LPA activates PKD in a dose-de-
pendent manner. Confluent and quiescent cultures of RK cells were
incubated with various concentrations of LPA for 10 min at 37 °C. Cells
were lysed with lysis buffer and immunoprecipitated with PA-1 anti-
serum. Top panel, in vitro kinase (IVK), PKD activity was determined
by an in vitro kinase assay as described under “Experimental Proce-
dures.” followed by SDS-PAGE and autoradiography. The autoradio-
gram shown is representative of three independent experiments. Mid-
dle panel, pS744, cell lysates from the experiments described above
were analyzed by SDS-PAGE and transferred to Immobilon mem-
branes. Western blot analysis was carried out using pS744/748 PKD
antibody. Bottom panel, scanning densitometry. The results shown are
the values (mean  S.E. n  3) of the level of PKD activation by in vitro
kinase obtained from scanning densitometry expressed as a percentage
of the maximum increase in phosphorylation obtained with 3 
M LPA.
Inset, PKD activity in the immunocomplexes was measured by syn-
tide-2 phosphorylation, as described under “Experimental Procedures.”
The results expressed as an increased -fold over control in phosphoryl-
ation represent the mean  S.E. obtained from three independent
experiments, each performed in duplicate. B, LPA induces PKD activa-
tion through a PLC/PKC-dependent pathway. Confluent and quiescent
RK cells were incubated for 1 h with the PKC inhibitor GF-109203X
(GF1, 3.5 
M) or Ro 31-8220 (Ro, 2.5 
M), or with PLC inhibitor,
U73122. Control cells () received equivalent amounts of solvent or
GFV. The cultures were subsequently stimulated for 10 min with 3 
M
LPA or 200 nM PDB at 37 °C. Cells were lysed with lysis buffer and
immunoprecipitated with PA-1 antiserum. Top panels, in vitro kinase
(IVK), PKD activity was determined by an in vitro kinase assay, as
described under “Experimental Procedures.” The autoradiogram shown
is representative of three independent experiments. Middle panels,
pS744, cell lysates from the experiments described as the above were
analyzed by SDS-PAGE and transferred to Immobilon membranes.
Western blot analysis was carried out using pS744/748 PKD antibody.
Bottom panels, PKD activity in the immunocomplexes was measured by
syntide-2 phosphorylation, as described under “Experimental Proce-
dures.” The results expressed as an increased -fold over control in
phosphorylation represent the mean  S.E. obtained from three inde-
pendent experiments, each performed in duplicate.
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syntide-2 phosphorylation (bottom). Previously, we demon-
strated that GF I and Ro 31-8220 do not inhibit PKD activity
when added directly to the in vitro kinase assay at identical
concentrations to those required to block PKD activation by
LPA in RK cells (9, 11). Thus, the results shown in Fig. 1B
imply that GF I and Ro 31-8220 do not inhibit PKD activity
directly but interfere with LPA-induced PKD activation and
activation loop phosphorylation in intact RK cells by blocking
PKC.
To determine whether LPA induces PKD activation and
phosphorylation through a PLC-dependent pathway in RK
cells, cultures of these cells were treated with the aminosteroid
U73122, an inhibitor of PLC (66, 67), prior to stimulation with
LPA. As shown in Fig. 1B (right, top and middle panels), 2 
M
U73122 markedly reduced PKD activation and Ser-744 phos-
phorylation in response to the subsequent addition of LPA.
Similar results were obtained when PKD activity in immuno-
complexes was determined by assays of syntide-2 phosphoryl-
ation (Fig. 1B, right bottom panel). The inhibitory effect of
U73122 was selective because treatment with this compound
did not interfere with PKD activation and Ser-744 phosphoryl-
ation induced by PDB (Fig. 1B).
Effect of Treatment with PTx on LPA-induced PKD Activa-
tion in RK Cells—Previous studies demonstrated that LPA
induces PKD activation through a PTx-sensitive pathway in
3T3 (18) and IEC-6 cells (57) but through a pathway that was
only partially attenuated by PTx in IEC-18 cells (57). Because
PTx catalyzes the ADP-ribosylation and inactivation of mem-
bers of the Gi family (68), these results indicated that Gi
contributes to PKD activation to a different degree in different
cell contexts.
To assess the contribution of Gi to LPA-induced PKD activa-
tion in RK cells, cultures of these cells were treated with
increasing concentrations of PTx (1–100 ng/ml) for 3 h and then
challenged with 3 
M LPA for 10 min. As illustrated by Fig. 2A,
treatment of RK cells with PTx at a concentration as high as
100 ng/ml attenuated only slightly PKD activation and Ser-744
phosphorylation in response to LPA (the maximal attenuation
was only 25%). Similar attenuation of PKD activation was
obtained when PKD activity in immunocomplexes was deter-
mined by phosphorylation of the exogenous substrate syntide-2
rather than by autophosphorylation (Fig. 2B). These results
suggest that LPA induces PKD activation predominantly
through Gi-independent pathways in RK cells, presumably in-
volving Gq/11 and/or G12/13.
LPA-induced PKD Activation Requires Functional Gq—Most
cell types express multiple members of the Gq and G12 families
with overlapping functions, thus rendering it difficult to ana-
lyze the contribution of these G proteins to heptahelical recep-
tor signaling. To circumvent this problem and in view of the
results presented above, we next examined whether LPA in-
duces PKD activation in murine embryonic fibroblasts gener-
ated from double knockout mice for Gq/11 and G12/13. As
illustrated by the Western blot analysis of cell lysates shown in
Fig. 3A, Gq/11 KO cells did not express either Gq or G11
whereas the G12/13 KO cells did not express either G12 or
G13 while, as expected, the RK cells express the  subunits of
these G proteins.
In agreement with the results shown in Figs. 1 and 2, treat-
ment of RK cells with either LPA or PDB induced a marked
increase in PKD catalytic activity measured either by auto-
phosphorylation or syntide-2 phosphorylation assays (Fig. 3B).
In striking contrast, addition of LPA to cultures of Gq/11 KO
cells did not induce any significant increase in PKD activity, as
measured in immunocomplexes by either autophosphorylation
or syntide-2 phosphorylation assays. PDB, which acts directly
on PKC and thus, bypasses the receptor-G protein interaction,
induced robust stimulation of PKD activity in Gq/11 KO cells,
indicating that the block in LPA action in these cells is up-
stream of the PKC/PKD cascade.
To further confirm the requirement of functional Gq in LPA-
induced PKD activation, we examined whether transfection of
Gq/11 KO cells with wild type Gq restores the ability of LPA to
induce PKD activation. Because PKD is abundantly expressed
in Gq/11 KO cells and RK cells, we used GFP-tagged PKD
(GFP-PKD) for these co-transfection experiments and GFP an-
tibody to immunoprecipitate the ectopically expressed PKD.
Previously, we demonstrated that the GFP tag does not inter-
fere with the regulatory properties of PKD (69, 70). Gq/11 KO
cells were co-transfected with GFP-PKD, either alone or to-
FIG. 2. Effect of PTx on the activation of PKD induced by LPA
in RK cells. A and B, confluent and quiescent RK cells were incubated
with different concentrations of PTx as indicated for 3 h. Cells were
then stimulated with () or without () 3 
M LPA (left panels) or 200
nM PDB (right panels) for 10 min at 37 °C. Cultures were lysed with
lysis buffer and then immunoprecipitated with PA-1 antiserum. A, top
panels, in vitro kinase (IVK), immunoprecipitates were subjected to in
vitro kinase assay, SDS-PAGE, and autoradiography. The autoradio-
graph shown is representative of three independent experiments. Mid-
dle panels, pS744, cell lysates from the experiments described as above
were analyzed by SDS-PAGE and transferred to Immobilon mem-
branes. Western blot analysis was carried out using pS744/748 PKD
antibody. Bottom panels, scanning densitometry, the results shown are
the values (means  S.E. n  3) of the level of PKD activation obtained
from scanning densitometry expressed as a percentage of the maximum
increase in phosphorylation obtained with 3 
M LPA for 10 min at
37 °C. , values corresponding to PKD activity from cells incubated
with PTx, and then stimulated with LPA; , values corresponding to
PKD activity from cells incubated with PTx but without LPA. B, PKD
activity in the immunocomplexes was measured by syntide-2 phospho-
rylation, as described under “Experimental Procedures.” The results
expressed as an increased -fold over control in phosphorylation repre-
sent the mean  S.E. obtained from three independent experiments,
each performed in duplicate.
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gether with pcDNA1-Gq, and the RK cells transfected with
GFP-PKD were used as the control. Three days after transfec-
tion, the transfected cells were stimulated without or with 3 
M
LPA or 200 nM PDB. PKD was immunoprecipitated from the
lysates of transfected cells with GFP antibody, and the immune
complexes were incubated with [-32P]ATP, subjected to SDS-
PAGE, and analyzed by autoradiography to detect the promi-
nent 140-kDa autophosphorylated GFP-PKD. The results pre-
sented in Fig. 4 show that Gq/11 KO cells cotransfected with
wild type Gq and PKD exhibit a marked increase in LPA-
induced PKD activity (Fig. 4A) and Ser-744 phosphorylation
(Fig. 4B) compared with Gq/11 KO cells transfected with GFP-
PKD alone. The increased PKD activity and phosphorylation in
Gq/11 KO cells cotransfected with wild type Gq is comparable
with that in the control RK cells transfected with GFP-PKD,
which express endogenous Gq. These results demonstrate
that a functional Gq/11 pathway is necessary for mediating
LPA-induced PKD activation.
LPA-induced Maximal PKD Activation Requires Functional
G12/13—Recently, we demonstrated that G13 contributes to
PKD activation through a Rho- and PKC-dependent signaling
pathway and hypothesized that PKD activation is mediated by
both Gq and G13 in response to acute bombesin receptor
stimulation (39). To assess the role of G12/13 in PKD activation
induced by LPA, we examined the effect of this agonist on PKD
activity in G12/13 KO cells. As shown in Fig. 3, addition of 5 
M
LPA to cultures of G12/13 KO cells induced a lower level of
PKD activation than that induced by either PDB in these cells
or by LPA in RK cells. These results imply that whereas Gq/11
are necessary for LPA-induced PKD activation, G12/13 are
required for eliciting maximal LPA-induced PKD activation.
FIG. 3. Comparison of three cell lines (RK, Gq/11 KO, or G12/13
KO) in G subunit expression and PKD activation induced by
LPA or PDB. A, Western blot analysis (W. Blot) of RK, Gq/11, and G12/13
knockout cell lysates. Confluent and quiescent cultures of the three type
cells were solubilized with 2 sample buffer. The lysates were analyzed
by SDS-PAGE and transferred to Immobilon membranes. Western blot
analysis was carried out using the antibody against q/11, 12, or 13.
The positions of immunoreactive G subunits at apparent Mr 43,000
are indicated by the arrows to the left. B, confluent and quiescent
cultures of RK cells were incubated with () or without () 3 
M LPA
or 200 nM PDB for 10 min at 37 °C. Cells were lysed with lysis buffer
and immunoprecipitated with PA-1 antiserum. Upper panel, IVK, PKD
activity was determined by an in vitro kinase assay as described under
“Experimental Procedures,” followed by SDS-PAGE and autoradiogra-
phy. The autoradiogram shown is representative of three independent
experiments. Middle panel, scanning densitometry. The results shown
are the values (mean  S.E. n  3) of the level of PKD activation by in
vitro kinase obtained from scanning densitometry expressed as a per-
centage of the maximum increase in phosphorylation obtained with 200
nM PDB. Lower panel, PKD activity in the immunocomplexes was then
measured by syntide-2 phosphorylation, as described under “Experi-
mental Procedures.” The results expressed as an increased -fold over
control in phosphorylation represent the mean  S.E. obtained from
three independent experiments, each performed in duplicate.
FIG. 4. LPA induces PKD activation in Gq/11 KO cells trans-
fected with Gq. A and B, Gq/11 KO cells co-transfected with GFP-PKD
and pcDNA1 or pcDNA1 encoding wild type Gq. The control cells (RK
cells) were transfected with GFP-PKD and pcDNA1, as indicated in this
figure. Three days after transfection, the cultures were left unstimu-
lated () or stimulated () either with 3 
M LPA or with 200 nM PDB
for 10 min and lysed. A, upper panel, the lysates were immunoprecipi-
tated with GFP antibody and PKD activity in the immunocomplexes
was determined by an in vitro kinase assay (IVK) as described under
“Experimental Procedures,” followed by SDS-PAGE and autoradiogra-
phy. A representative autoradiogram of three independent experiments
is shown. Lower panel, PKD activity in immunocomplexes was meas-
ured by syntide-2 phosphorylation. The results expressed as an in-
creased -fold over control in phosphorylation represent the mean S.E.
obtained from three independent experiments. B, cell lysates from the
experiments described as above were analyzed by SDS-PAGE and
transferred to Immobilon membranes. Western blot (W. Blot) analysis
was carried out using pS744/748 PKD antibody (upper panel) or GFP
antiserum (lower panel).
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The results presented in Fig. 5 were designed to examine in
more detail the stimulation of PKD activity in response to LPA
in G12/13 KO cells. LPA promoted PKD activation in G12/13
KO cells in a concentration-dependent fashion with half-max-
imal and maximal stimulation achieved at 0.07 and 3 
M. The
maximal increase in PKD autophosphorylation activity (4-fold)
was lower than that achieved by LPA in RK cells (6-fold). These
results confirmed that LPA stimulated PKD activation in
G12/13 KO cells with reduced effectiveness, even at the con-
centrations that induced a maximal response, and implied that
the expression of G12/13 is necessary for maximal stimulation
of PKD in response to LPA. The results shown in Fig. 5A also
demonstrate that LPA induced PKD Ser-744 phosphorylation
andsyntide-2phosphorylationactivity (inset) inaconcentration-
dependent manner in G12/13 KO cells.
We verified that LPA induces PKD activation in these cells
through a PKC- and PLC-dependent pathway. As shown in Fig.
5B, left, exposure to either GF I or Ro 31-8220 prevented PKD
FIG. 5. LPA activates PKD in a dose-dependent and PLC/PKC-dependent manner in G12/13 KO cells. A, LPA activates PKD in a
dose-dependent manner. Confluent and quiescent cultures of G12/13 knockout cells were incubated with various concentrations of LPA for 10 min
at 37 °C. Cells were lysed with lysis buffer and immunoprecipitated with PA-1 antiserum. Top panel, PKD activity was determined by an in vitro
kinase (IVK) assay as described under “Experimental Procedures,” followed by SDS-PAGE and autoradiography. The autoradiogram shown is
representative of three independent experiments. Middle panel, pS744, cell lysates from the experiments described as above were analyzed by
SDS-PAGE and transferred to Immobilon membranes. Western blot analysis was carried out using pS744/748 PKD antibody. Bottom panel,
scanning densitometry. The results shown are the values (mean  S.E. n  3) of the level of PKD activation by in vitro kinase obtained from
scanning densitometry expressed as a percentage of the maximum increase in phosphorylation obtained with 3 
M LPA. Inset, PKD activity in the
immunocomplexes was measured by syntide-2 phosphorylation, as described under “Experimental Procedures.” The results expressed as an
increased -fold over control in phosphorylation represent the mean  S.E. obtained from three independent experiments, each performed in
duplicate. B, LPA induces PKD activation through a PLC/PKC-dependent pathway. Confluent and quiescent G12/13 knockout cells were incubated
for 1 h with the PKC inhibitor GF-109203X (GF1, 3.5 
M) or Ro 31-8220 (Ro, 2.5 
M), or with PLC inhibitor, U73122. Control cells () received
equivalent amounts of solvent or GFV. The cultures were subsequently stimulated for 10 min with 3 
M LPA or 200 nM PDB at 37 °C. Cells were
lysed with lysis buffer and immunoprecipitated with PA-1 antiserum. Top panels, IVK, PKD activity was determined by an in vitro kinase assay,
as described under “Experimental Procedures.” The autoradiogram shown is representative of three independent experiments. Middle panels,
pS744, cell lysates from the experiments described as the above were analyzed by SDS-PAGE and transferred to Immobilon membranes. Western
blot analysis was carried out using pS744/748 PKD antibody. Bottom panels, PKD activity in the immunocomplexes was measured by syntide-2
phosphorylation, as described under “Experimental Procedures.” The results expressed as an increased -fold over control in phosphorylation
represent the mean  S.E. obtained from three independent experiments, each performed in duplicate.
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activation and Ser-744 phosphorylation induced by LPA
whereas the biologically inactive analog GFV did not prevent
PKD activation in response to LPA. Similarly, treatment with
the PLC inhibitor U73122 (66, 67) prevented PKD activation
induced by LPA but not by PDB, as shown by assays of auto-
phosphorylation, Western blot analysis, or syntide-2 phospho-
rylation (Fig. 5B, right).
LPA-induced PKD Activation and Phosphorylation Requires
Functional Gi in G12/13 KO Cells—We hypothesized that PKD
activation and activation loop phosphorylation are elicited by
LPA and other GPCR agonists through interaction of comple-
mentary G protein pathways, namely, Gq, G12/13, and Gi (see
Introduction for references). Although the effect of Gi is not
prominent in LPA-induced PKD activation in RK cells, our
hypothesis predicts that in G12/13 KO cells, members of the Gq
family interact with members of the Gi family in mediating
LPA-induced PKD activation. To test the contribution of Gi to
LPA-induced PKD activation in G12/13 KO cells, cultures of
these cells were treated with increasing concentrations of PTx
(1–100 ng/ml) and PKD activity in immunocomplexes was
measured by either autophosphorylation or syntide-2 phospho-
rylation assays.
As shown in Fig. 6A, treatment with PTx dramatically in-
hibited both PKD activation and Ser-744 phosphorylation elic-
ited by LPA in a concentration-dependent fashion. Indeed,
treatment with 30–100 ng/ml PTx completely abolished PKD
activation and Ser-744 phosphorylation in response to LPA. In
contrast, treatment with 50 ng/ml PTx did not interfere with
PKD activation and Ser-744 phosphorylation induced by PDB
in these cells. As illustrated in Fig. 6B, similar results were
obtained when PKD activity in immunocomplexes was deter-
mined by assays of syntide-2 phosphorylation. These findings
contrast with those shown in Fig. 2 with RK cells (PTx inhib-
ited LPA-induced PKD activation by only 25%) and indicate
that Gi plays a critical role in promoting PKD activation in
G12/13 KO cells. We conclude that in G12/13 KO cells, Gi
cooperates with Gq in mediating the PKC/PKD phosphoryla-
tion cascade in response to LPA.
Recently, we demonstrated that in addition to Gq, G13-
mediated signaling contributes to PKD activation in bombesin-
stimulated cells through endogenous Rho (39). C. difficile toxin
monoglucosylates the threonine residue at position 35 in Rac
and Cdc-42 and threonine 37 in Rho and thereby inactivates
these small G proteins (71, 72). In view of the results shown in
Fig. 6 with G12/13 KO cells, we hypothesized that inactivation
of Rho GTPases with C. difficile toxin B in RK cells should
enhance the sensitivity of LPA-induced PKD activation to
treatment with PTx. To test this hypothesis, RK cells were
treated with PTx either with or without C. difficile toxin B and
then stimulated with either LPA or PDB, as indicated in Fig. 7.
Treatment with C. difficile toxin B markedly enhanced the
ability of PTx to inhibit LPA-induced PKD activation (Fig. 7A)
and Ser-744 phosphorylation (Fig. 7B) in RK cells. These re-
sults provide an independent line of evidence indicating that
PKD activation induced by LPA is mediated by cooperation of
multiple G protein pathways.
LPA Induces Activation of Mitogen-activated Protein Kinases
via Gi-dependent but PKC-independent Pathways in RK,
Gq/11 KO, and G12/13 KO Cells—To substantiate that the
different profiles of PKD activation in response to LPA in the
three cell lines used in our study is specific and reflects the
participation of multiple G proteins, we examined other biolog-
ical effects induced by LPA in these cells.
In most cell types, LPA stimulates Ras activation leading to
stimulation of Raf, MEK, and the ERKs via a PTx-sensitive
pathway that involves the  subunits of Gi (47–51). Here, we
determined the effect of PTx on LPA-induced ERK activation in
these three types of cells. As shown by Western blot analysis
using an antibody that detects the dually phosphorylated and
active ERK-1 and ERK-2, LPA induced robust activation of the
ERKs in RK, G12/13 KO, and Gq/11 KO cells (Fig. 8). Treat-
ment with PDB also induced strong ERK activation in the
three cell lines, indicating the existence of a PKC-dependent
pathway.
Treatment of RK cells with PTx markedly inhibited ERK
activation in response to LPA, whereas exposure to GF I or Ro
31-8220 did not interfere with ERK activation, indicating that
LPA induces ERK through a PTx-sensitive, PKC-independent
in RK cells. Virtually identical results were obtained with
G12/13 KO cells and Gq/11 KO cells. Specifically, LPA pro-
FIG. 6. Effect of PTx on the activation of PKD induced by LPA
in G12/13 KO cells. A and B, confluent and quiescent G12/13 KO cells
were incubated with different concentration of PTx as indicated for 3 h.
Cells were then stimulated with () or without () 3 
M LPA (left
panels) or 200 nM PDB (right panels) for 10 min at 37 °C. Cultures were
lysed with lysis buffer and then immunoprecipitated with PA-1 anti-
serum. A, top panels, in vitro kinase (IVK), immunoprecipitates were
subjected to in vitro kinase assay, SDS-PAGE, and autoradiography.
The autoradiograph shown is representative of three independent ex-
periments. Middle panels, cell lysates from the experiments described
above were analyzed by SDS-PAGE and transferred to Immobilon
membranes. Western blot analysis was carried out using pS744/748
PKD antibody. Bottom panels, scanning densitometry, the results
shown are the values (mean S.E., n 3) of the level of PKD activation
obtained from scanning densitometry expressed as a percentage of the
maximum increase in phosphorylation obtained with 3 
M LPA for 10
min at 37 °C. , values corresponding to PKD activity from cells incu-
bated with PTx, and then stimulated with LPA; , values correspond-
ing to PKD activity from cells incubated with PTx but without LPA. B,
PKD activity in the immunocomplexes was measured by syntide-2
phosphorylation, as described under “Experimental Procedures.” The
results expressed as an increased -fold over control in phosphorylation
represent the mean  S.E. obtained from three independent experi-
ments, each performed in duplicate.
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moted ERK activation in both G12/13 KO cells and Gq/11 KO
cells through a Gi-dependent but PKC-independent pathway
(Fig. 8). These results demonstrate that the lack of expression
of these G proteins does not interfere with other biological
effects of LPA mediated by Gi and provide further support to
the conclusion that LPA utilizes different G protein pathways
to activate parallel phosphorylation cascades leading to PKD
and ERK activation in RK cells.
Concluding Remarks—LPA promotes a broad range of bio-
logical responses and multiple molecular events in target cells
(42). Consistent with the stimulation of multiple signaling
pathways, LPA has been shown to activate several heterotri-
meric G proteins including Gq, Gi, and G13 in Swiss 3T3 cells
(54). PKC-dependent PKD activation has been identified as an
early event in the action of LPA in intact Swiss 3T3, Rat-1, and
IEC-6 cells (56, 57). Because our previous studies indicated
that Gq- and G13-mediated signaling can promote PKD ac-
tivation in intact cells (20, 39), it was surprising that treatment
of these cells with PTx markedly inhibited PKD activation in
response to LPA (56, 57). Because PTx catalyzes the ADP-
ribosylation and inactivation of members of the Gi family (68),
these results identified the involvement of an additional Gi-de-
pendent pathway leading to PKD activation in response to
LPA. However, other results also demonstrated that LPA in-
duces PKD activation through a pathway that was only par-
tially attenuated by PTx in IEC-18 cells (57) indicating that Gi
contributes to PKD activation to different degrees in different
cell contexts. In the present study, we tested the hypothesis
that LPA induces PKD activation through multiple G protein
signal transduction pathways, including Gq, Gi, and G13, using
mouse embryonic cell lines deficient in Gq/11 and G12/13 and
using a cell line deficient in rhodopsin kinase (RK cells), as a
control.
Based on the results presented in this study, we propose a
model that envisages that LPA induces PKD activation
through Gq acting synergistically with G12 and Gi. Thus, inhi-
bition of Gi signaling in RK cells by treatment with PTx only
induces a modest attenuation of PKD activation in response to
LPA because the remaining G protein pathways (Gq and G12)
cooperate to mediate a substantial response to LPA. Similarly,
treatment of RK cells with C. difficile toxin B that inactivates
FIG. 7. PKD activation induced by LPA in RK cells is partially
blocked by C. difficile toxin B (toxin B) and almost abolished by
the combination treatments of the cells with toxin B and Ptx. A
and B, confluent and quiescent RK cells were preincubated with () or
without () PTx (50 ng/ml) for 3 h and then treated with different
concentrations of toxin B as indicated for 1.5 h. Cells were then stim-
ulated with () or without () 3 
M LPA or 200 nM PDB for 10 min at
37 °C. Cultures were lysed with lysis buffer and then immunoprecipi-
tated with PA-1 antiserum. A, upper panel, in vitro kinase (IVK),
immunoprecipitates were subjected to in vitro kinase assay, SDS-
PAGE, and autoradiography. The autoradiograph shown is represent-
ative of three independent experiments. Lower panel, PKD activity in
the immunocomplexes was measured by syntide-2 phosphorylation, as
described under “Experimental Procedures.” The results expressed as
an increased -fold over control in phosphorylation represent the mean
S.E. obtained from three independent experiments, each performed in
duplicate. B, pS744, cell lysates from the experiments described above
were analyzed by SDS-PAGE and transferred to Immobilon mem-
branes. Western blot analysis was carried out using pS744/748 PKD
antibody.
FIG. 8. LPA induces activation of ERK-2 and ERK-1 in RK cells
and Gq/11 KO or G12/13 KO cells. Confluent and quiescent RK cells (A)
and Gq/11 KO cells (B) or G12/13 KO cells (C) were incubated with PTx
for 3 h or with the other inhibitors, GF-109203X (GF1, 3.5 
M), or Ro
31–8220 (Ro, 2.5 
M), or U0126 (U, 2.5 
M), as indicated, for 1 h.
Control cells () received an equivalent amount of solvent. Cells were
then stimulated with () or without () 3 
M LPA or 200 nM PDB for 10
min at 37 °C. Cultures were lysed with lysis buffer. Cell lysates from
the experiments were analyzed by SDS-PAGE and transferred to Im-
mobilon membranes. A–C, upper panels, Western blot analysis with
specific antiphospho-ERK-1/2 monoclonal antibody; lower panels, the
Western blot was also probed for total ERK by ERK-2 polyclonal
antibody.
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Rho GTPases, the effectors of the G12 pathway, had little effect
on PKD activation by LPA because the remaining G protein
pathways (in this case Gq and Gi) are sufficient to mediate PKD
activation in response to LPA. An important result substanti-
ating our hypothesis is that treatment of RK cells with both
C. difficile toxin B and PTx completely prevented LPA-induced
PKD activation, indicating that endogenous Gq appears neces-
sary but not sufficient to mediate this response.
The salient features of this model are corroborated by the
results obtained in the cell lines deficient in either Gq/11 or
G12/13. A crucial role of Gq/11 in mediating LPA-induced PKD
activation is clearly demonstrated by the fact that LPA-induced
PKD activation was completely abrogated in Gq/11 KO cells
and that transfection of Gq into the Gq/11 KO cells restored
LPA-induced PKD activation to the similar level as the control
cells. In G12/13 KO cells, LPA induced substantial PKD acti-
vation, a response predicted by the model to be mediated by
cooperation of Gq and Gi. In line with this interpretation and in
sharp contrast to the results obtained with RK cells, treatment
of G12/13 KO cells with PTx dramatically inhibited PKD acti-
vation in response to LPA. These results are also consistent
with the notion that endogenous Gq/11 is not sufficient to
mediate PKD activation in response to LPA. Thus, our model
integrates the PTx-sensitive and -insensitive effects obtained
in G12/13 KO cells and RK cells with the striking suppression
of LPA-induced PKD activation in Gq/11 KO cells and leads to
the notion that LPA induces PKD activation through the syn-
ergistic interaction of pathways initiated by Gq, G12, and Gi. A
corollary of these results is that the level of expression of the
different  subunits of heterotrimeric G proteins can be iden-
tified as one of the important molecular elements that deter-
mine the influence of cell context on agonist-induced PKD
activation.
Recent work from other laboratories has shown that tran-
scriptional responses induced by LPA also result from syner-
gistic effects between parallel G protein signaling pathways.
For example, the stimulation of the transcription factor NF-B
by LPA is mediated by Gq and Gi pathways (73) and the
activation of the serum response element is mediated by coop-
erative effects between Gi and G13/Rho pathways (74). Fur-
thermore, recent genetic studies indicate that the Gq-mediated
signaling pathway functionally interacts with the G12-medi-
ated signaling pathway to promote embryonic survival (63).
Here, we propose that PKD activation, which precedes the
transcriptional responses, is also mediated by cooperative ef-
fects between events initiated by Gq, Gi, and G12. In this man-
ner, PKD may constitute an early point of convergence of Gq,
G12, and Gi signaling in LPA-treated cells. The scheme shown
in Fig. 9 summarizes the multiple G protein signal transduc-
tion pathways involved in LPA-induced PKD activation pro-
posed in this study and also illustrates the molecular, cellular,
and pharmacological approaches used in our experiments.
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